SLNO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLNO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Soleno Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was $0.92 Mil. Soleno Therapeutics's average total debt for the quarter that ended in Dec. 2024 was $27.93 Mil. Therefore, Soleno Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 3.31%.
The historical data trend for Soleno Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soleno Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | 0.87 |
Soleno Therapeutics Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | 3.31 | 10.31 |
For the Biotechnology subindustry, Soleno Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Soleno Therapeutics's Effective Interest Rate on Debt % falls into.
Soleno Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2023 ) | + | Total Debt (A: Dec. 2024 )) | / count ) |
= | -1 * -0.231 | / | ( (0.403 | + | 52.826) | / 2 ) |
= | -1 * -0.231 | / | 26.6145 | |||
= | 0.87 % |
where
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.13 | + | 0.273 |
= | 0.403 |
Total Debt (A: Dec. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 52.3 | + | 0.526 |
= | 52.826 |
Soleno Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Sep. 2024 ) | + | Total Debt (Q: Dec. 2024 )) | / count ) |
= | -1 * -0.924 | / | ( (3.029 | + | 52.826) | / 2 ) |
= | -1 * -0.924 | / | 27.9275 | |||
= | 3.31 % |
where
Total Debt (Q: Sep. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 2.581 | + | 0.448 |
= | 3.029 |
Total Debt (Q: Dec. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 52.3 | + | 0.526 |
= | 52.826 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Soleno Therapeutics (NAS:SLNO) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Soleno Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Patricia C Hirano | officer: See Remarks | 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Vivo Opportunity Fund Holdings, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Matthew Pauls | director | 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852 |
Bhatnagar Anish | director, officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
Kristen Yen | officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
James H Mackaness | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Vivo Opportunity, Llc | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Abingworth Bioventures Vii Lp | 10 percent owner | PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Jack W Schuler | 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Carlyle Holdings I L.p. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Holdings I Gp Sub L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
From GuruFocus
By Marketwired • 11-26-2024
By Marketwired • 11-14-2024
By GuruFocus News • 04-14-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 03-01-2025
By Marketwired • 03-26-2025
By GuruFocus News • 02-15-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 01-29-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.